Cargando…

Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia

BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez-Egea, Emilio, Worbe, Yulia, Bernardo, Miguel, Robbins, Trevor W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236440/
https://www.ncbi.nlm.nih.gov/pubmed/29455687
http://dx.doi.org/10.1017/S003329171800017X
_version_ 1783371034106265600
author Fernandez-Egea, Emilio
Worbe, Yulia
Bernardo, Miguel
Robbins, Trevor W.
author_facet Fernandez-Egea, Emilio
Worbe, Yulia
Bernardo, Miguel
Robbins, Trevor W.
author_sort Fernandez-Egea, Emilio
collection PubMed
description BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. RESULTS: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. CONCLUSIONS: Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients.
format Online
Article
Text
id pubmed-6236440
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-62364402018-11-19 Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia Fernandez-Egea, Emilio Worbe, Yulia Bernardo, Miguel Robbins, Trevor W. Psychol Med Original Articles BACKGROUND: Obsessive-compulsive disorder (OCD) is common in clozapine-treated patients although the actual prevalence, phenomenology and risk factors remain unclear. The aim of the present study was to address the three aforementioned questions. METHODS: The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. RESULTS: OCD prevalence was 47%, higher in patients on poly-pharmacy than on monotherapy (64% vs 31%; p = 0.001). Two OCI-R factors had significantly higher scores and distinct risk factors: checking behaviour (mean = 5.1; SD = 3.6) correlated with length of clozapine treatment (r = 0.21; p = 0.026), and obsessing factor (mean = 4.8; SD = 3.6) correlated with psychosis severity (r = 0.59; p = 0.001). These factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. CONCLUSIONS: Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs with potent antiserotoninergic properties, should be widely adopted by clinicians. Further research is needed to understand the pathophysiology underlying repetitive behavior onset in clozapine-treated patients. Cambridge University Press 2018-12 2018-02-19 /pmc/articles/PMC6236440/ /pubmed/29455687 http://dx.doi.org/10.1017/S003329171800017X Text en © Cambridge University Press 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Fernandez-Egea, Emilio
Worbe, Yulia
Bernardo, Miguel
Robbins, Trevor W.
Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title_full Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title_fullStr Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title_full_unstemmed Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title_short Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
title_sort distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236440/
https://www.ncbi.nlm.nih.gov/pubmed/29455687
http://dx.doi.org/10.1017/S003329171800017X
work_keys_str_mv AT fernandezegeaemilio distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia
AT worbeyulia distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia
AT bernardomiguel distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia
AT robbinstrevorw distinctriskfactorsforobsessiveandcompulsivesymptomsinchronicschizophrenia